Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 02/23/23
Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma ConferenceGlobeNewsWire • 02/09/23
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater ChinaGlobeNewsWire • 11/29/22
Aclaris Therapeutics to Participate in Two November Healthcare Investor ConferencesGlobeNewsWire • 11/10/22
Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 11/08/22
Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor RelationsGlobeNewsWire • 09/27/22
Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 08/30/22
Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia AreataGlobeNewsWire • 08/25/22
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/03/22
Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 08/03/22
Here's Why Aclaris Therapeutics (ACRS) is a Great Momentum Stock to BuyZacks Investment Research • 07/15/22
Does Aclaris (ACRS) Have the Potential to Rally 141% as Wall Street Analysts Expect?Zacks Investment Research • 06/13/22
Has Aclaris Therapeutics (ACRS) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 06/06/22
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 179%: Here's is How to TradeZacks Investment Research • 05/27/22
Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/16/22
Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 05/10/22
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/24/22